Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules.

Yoshihisa IshiuraShosaku NomuraYuka IshiiKai ImaiKahori NakahamaYusuke SawaiTakeshi TamakiToshiki ShimizuNaoyuki MiyashitaTomoki Ito

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

There are no current guidelines for oral targeted therapy in patients with swallowing disturbance, but alectinib administered orally by opening the capsules and suspending the contents in water can be a treatment option in patients with ALK-positive NSCLC and swallowing difficulty.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
case report
clinical practice
tyrosine kinase